LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback